Women Named Beacon of Hope for Fight against Cancer
"Denise Maguire has been designated an official “Beacon of Hope” – for her extraordinary fight against the cancer that has invaded almost EVERY part of her body.
The former barrister and university lecturer from Parkgate received a Special Commendation from the Lymphoma Association for inspiring scores of other cancer patients, while suffering so much herself.
Denise, 48, was diagnosed with advanced lymphoma in January last year.
She told the Times: “I had tumours in all my glands – my neck, my groin, my lungs, my abdomen and bone marrow were all affected.
“I was generally tired and aware of one or two lumps and bumps – but I had had cancer for years without realising it.
“Operating was never an option and lymphoma is incurable, but chemotherapy has helped and when I got one set of results my oncologist at Sheffield’s Weston Park Hospital literally cartwheeled down the ward.”"
Read More: http://www.southyorkshiretimes.co.uk/news/local/dearne-area/denise_named...
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
